BridgeBio Pharma, Inc. (NASDAQ: BBIO) on Sunday presented data from the ATTRibute-CM study. The study showed that acoramidis reduced cumulative cardiovascular outcomes, including cardiovascular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback